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Abstract
Background: Recent discoveries of the atherosclerosis-related miRNAs shed new light on the treatment of
cardiovascular diseases. Of note, miR-106b ~ 25 cluster and miR-17 ~ 92 cluster are paralogs. Up till now, plenty
of researches have shown the role of miR-17 ~ 92 cluster in tumor and atherosclerosis, but miR-106b ~ 25
cluster has stayed mysterious in atherosclerosis field. This study was designed to investigate how miR-106b
functions in the atherosclerosis-related angiogenesis and to explore the functioning processes of miR-106b, so
as to seek out a new target for the treatment of atherosclerosis.
Methods: Up and down regulation of miR-106b expression was achieved through transfection in HUVECs so as
to investigate the function of miR-106b. Next we predicted the target genes of miR-106b and detected them
using qRT-PCR and Western blot technique. At last, luciferase assay was conducted to verify the direct target
gene of miR-106b. Data are expressed as mean ± SEM. Two treatment groups were compared by Mann–Whitney U
test or student’s t-test. Results were considered statistically significant when P < 0.05.
Results: The results showed miR-106b up-regulation groups formed less tubes than control groups while the down-
regulation groups showed the opposite. Meanwhile, no obvious effect on apoptosis was observed in endothelial cells.
Next we predicted the target genes of miR-106b and finally settled down to MAPK14 (Mitogen-Activated Protein
Kinase), STAT3 (Signal Transducers and Activators of Transcription 3), JAK1(Janus Kinase 1) and VEGFA(Vascular Endothelial
Growth Factor A) as candidate target genes. Our results revealed over-expressed miR-106b represses STAT3 expression,
while miR-106b inhibition resulted in STAT3 up-regulation. Ultimately, luciferase assay confirmed STAT3 mRNA is the direct
target of miR-106b.
Conclusions: Our research demonstrated that miR-106b modulate angiogenesis in endothelial cells through affecting
expression of STAT3, which occurs by direct target action. Therefore, we affirmed that miR-106b exerts an anti-angiogenic
effect in endothelial cells via STAT3-involved signaling pathway, via directly targeting STAT3.
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Background
Vascular generation also known as neovascularization refers
to vasculogenesis, angiogegnesis and arteriogenesis [1, 2].
In this study, we focused mainly on the angiogenesis pro-
cess.Angiogenesis is the process of generating new capillary
blood vessels. Physiologically, angiogenesis could be found
in wound healing, infections, female reproductive system
and also embryogenesis [2, 3]. Unregulated angiogenesis
may result in different pathologies such as atherosclerosis,
diabetic retinopathy, rheumatoid arthritis and tumor etc
[2]. Many atherosclerotic lesions are vascularized by a net-
work of capillaries that arise from the adventitial vasa
vasorum. These capillaries may be important regulators of
plaque instability. Reflecting their inflammatory microenvir-
onment, the capillaries are immature endothelial tubes with
disorganized branching, fragile and prone to rupture. The
accumulation of erythrocytes after intraplaque hemorrhage
which contains phospholipids and free cholesterol may pro-
mote stable plaque to transform into unstable lesion,
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increasing the probability of cardiovascular events [4]. Stud-
ies have shown that the proliferation rates of endothelial
cells in plaque capillaries range from undetectable to 43 %,
which indicates these vessels are found in various stages of
development [5, 6], revealing the key role of endothelial
cells in the whole process. Other studies showed that long-
term treatment with recombinant murine endostatin or
TNP-470 significantly reduced the further growth of ath-
erosclerosis without affecting cholesterol levels [6], which
strongly support that intimal capillaries contribute to the
progression of atherosclerosis.
Recent discoveries of the atherosclerosis-related miR-
NAs provoked some thoughts about the diagnosis and
treatment of cardiovascular diseases [7]. MiRNAs are a
large class of evolutionarily conserved, small, non-
coding RNAs, typically 22 nucleotides in length, which
primarily function post-transcriptionally by interacting
with the 3′untranslated region (UTR) of specific target
mRNAs in a sequence-specific manner. MiRNAs have
emerged as central regulators of many cardiogenic pro-
cesses [8]. In the whole history of miRNAs studying,
miR-17 ~ 92 cluster was extremely famous for its
angiogenesis-related features, no matter in tumors or in
atherosclerotic diseases. As its paralog, miR-106b ~ 25
cluster’s role in atherosclerosis still remain to be eluci-
dated. Accordingly, our study mainly focused on how




Human umbilical vein endothelial cells (HUVECs) were
isolated from donated umbilical cords and cultivated in
ECM medium (Sciencell,Cat.No. 1001) supplemented
with ECGs (Sciencell, Cat. No. 1052) plus 5 % FBS (Cat.
No. 0025), and used until passage seven. 293 T cells were
obtained from Guangzhou RiboBio.Co.Ltd and cultured
under the recommended conditions.
Transfection
For transfection, HUVECs were cultured to 70 % conflu-
ence and transfected with 30nM miR-106b mimic
(Ambion, Cat. No.4464066) or miR-106 inhibitor (Ambion,
Cat. No.AM17000) oligonucleotides using Lipofectin (Invi-
trogen, Cat. No.18292-011) according to the manufac-
turer’s instructions. For miR-106b mimic transfection,
there were three different treatment groups prepared,
which were: mimic group (HUVECs transfected with miR-
106b mimic plus Lipofectin), mock group (HUVECs mixed
with only Lipofectin) and negative-control group
[HUVECs transfected with miRNA mimic negative control
(Ambion, Cat. No.4464058) plus Lipofectin]; similarly, for
transfection of miR-106b inhibitor, there were inhibitor
group (HUVECs transfected with miR-106b inhibitor plus
Lipofectin), mock group (HUVECs mixed with only Lipo-
fectin) and negative-control group [HUVECs transfected
with miRNA inhibitor negative control (Ambion, Cat.
No.4464076) plus Lipofectin]. For transfection of 293 T
cells with STAT3 plasmids, miR-106b mimic was trans-
fected with LipofectamineTM 2000 (Invitrogen, Cat.
No.11668027) to the plasmid/LipofectamineTM 2000 trans-
fection mix with the final concentrations of 50nM.
Tube formation assay
Forty eight hours after transfection, HUVECs 200ul (C =
2 × 105/ml) from different treatment groups were cultured
respectively in a 48-well plate (Corning) coated with
150 μl Matrigel Basement Membrane Matrix (BD Biosci-
ences) in each well. The number of formed tubes was
quantified after 24 h by counting the cumulative tube
number in five random microscopic fields, the average
number of each group was calculated and normalized to
the average number of negative-control group.
Flow cytometry analysis
For fixation, HUVECs after transfection were detached
with trypsin, fixed in 4 % formaldehyde for 10 min and
stored in 80 % ethanol. For permeabilization, cells
were incubated in 20 μg/ml proteinase K at room
temperature for 5 min and then treated with TdT
Labeling Reaction Mixture (MERCK, Cat. No.QIA39-
1EACN) at 37 °C for 1–1.5 h in the dark. Resuspend
cells in 1 × TBS and analyze cells on a FACS Canto II
device (BD).
RNA isolation and RT-PCR
Total RNA of HUVECs was isolated using Qiazol (Qiagen,
Cat. No.79306) according to the manufacturer’s protocol.
Subsequently, 1 μg of RNA from each sample was reverse
transcribed into cDNA and subjected to conventional
PCR. To assess the transfection efficiency in HUVECs
transfected with miR-106b mimic or inhibitor, we isolated
total RNA using Qiazol 24 h after transfection. RT-PCR
was performed using the TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Cat. No.4366596)
and primers which are specific for reverse transcription of
hsa-miR-106 and RNU44 (one cycle: 30 min at 16 °C,
30 min at 42 °C, 5 min at 85 °C). Real–time PCR was per-
formed using the Taqman MicroRNA Assay (Applied Bio-
systems, Cat. No.4427975) and Taqman Universal PCR
Master Mix II (Applied Biosystems, Cat. No.4440040) with
RNU44 as loading control. (One cycle: 10 min at 95 °C,
40 cycles: 15 s at 95 °C, 60 s at 60 °C).
To assess the predicted target genes (MAPK14, STAT3,
VEGFA and JAK1) relative expression, we isolated total
RNA as stated above and eliminated DNA with DNase I,
Amp Grade (Invitrogen, Cat. No.18068-015). RT-PCR
was performed using the High-Capacity cDNA Reverse
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Transcription Kits (Applied Biosystems, Cat. No.
4368814) (one cycle: 10 min at 25 °C, 120 min at 37 °C,
5 min at 85 °C). Real–time PCR was performed using
the Power SYBR Green PCR Master Mix (Applied Bio-
systems, Cat. No.4367659) and primers specific for amp-
lification of MAPK14, STAT3, VEGFA and JAK1 with
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)
as a reference gene. (One cycle: 10 min at 95 °C, 40 cy-
cles: 15 s at 95 °C, 60 s at 60 °C). The primers used were
as follows: MAPK14: forward: 5′-GAGCGTTACCAGA
ACCTGTCTC-3′, reverse: 5′-AGTAACCGCAGTTCTC
TGTAGGT-3′; STAT3: forward: 5′-CTTTGAGACC-
GAGGTGTATCACC-3′, reverse: 5′-GGTCAGCATGT
TGTACCACAGG-3′; VEGFA: forward: 5′-TTGCCTTG
CTGCTCTACCTCCA-3′, reverse: 5′-GATGGCAGTAG






For western blot analysis of STAT3 expression, cultured
cells were lysed in RIPA (Radio-Immunoprecipitation
Assay) buffer on ice and protein concentration was
quantified using the Bradford method. Equal amounts of
protein were loaded, subjected to SDS-PAGE (Sodium
dodecyl sulfate polyacrylamide gel electrophoresis) and
blotted on PVDF (Polyvinylidene Fluoride) transfer
membranes. Blots were incubated over night with anti-
bodies directed against human STAT3 or GAPDH as
a loading control. Proteins were probed with primary
antibodies and then with HRP (horseradish peroxidase)-
conjugated secondary antibodies. The enhanced chemi-
luminescence signal was detected using a densitometry
program (ChemiDoc XRS, BioRad). To quantify the
protein signal, we subtracted background and normal-
ized the value to GAPDH with ImageLab 4.0.
Luciferase reporter assay
293 T cells (Guangzhou RioBobio Co Ltd, China) (1.5 × 104
cells/well) were seeded in 96-well plates. The predicted
binding sequences on the 3′UTR of STAT3 were synthetic-
ally produced by PCR and transferred into a luciferase re-
porter vector. 100 ng of STAT3 3′-UTR luciferase reporter
plasmid (Guangzhou RioBobio Co Ltd, China) and either
50 nM miR-106b mimic oligonucleotide or a non-targeting
miRNA mimic control (Negative-Control) (Guangzhou
RioBobio Co Ltd, China) were co-transfected. All transfec-
tions were performed using the Lipofectamine™ 2000 in
OPTI-MEM I Reduced Serum Medium (100 μl/well) for
24 h. The luciferase activities from each well were mea-
sured using the Dual Glo Luciferase Assay System (Pro-
mega, USA) according to the manufacturer’s instruction.
Statistical analysis
Data are expressed as mean ± SEM. Two treatment
groups were compared by Mann–Whitney U test or stu-
dent’s t-test (GraphPad Prism 5.). Results were consid-
ered statistically significant when P < 0.05.
Results
Modulation of miR-106b Expression in Cultured HUVECs
To explore the specific role of miR-106b in angiogenesis,
we up or down regulated the expression of miR-106b in
endothelial cells by using specific miR-106b mimic or in-
hibitor in transfection, respectively. Mimics and inhibi-
tors with irrelevant nucleotide sequences served as
negative controls. We detected transfection efficiency by
quantitative real-time PCR which showed a strong
increase in miR-106b at 24 h after the mimic transfec-
tion, whereas transfection with inhibitor resulted in
Fig. 1 a, b MiR-106b relative expression in different groups after transfection. Quantitative real-time PCR shows a strong increase in miR-106b in
miR-106b mimic transfection group and a dramatic decline in miR-106b levels in miR-106b inhibitor transfection group, which explicitly guaranteed
the transfection efficiency. MiR-106b levels were normalized to RNU44, Data are presented as means ± SEM. **P <0.05 (n = 4)






Fig. 2 (See legend on next page.)
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significantly decreased miR-106b levels (Fig. 1), which
precisely confirmed that transfection procedures were
successfully accomplished.
Changes in general function of HUVECs after transfection
After transfection, we detected the apoptosis rate of the
HUVECs by using TUNEL assay. There was no signifi-
cant difference in cellular apoptosis after transfection
with the different compounds (Fig. 2a-d). The overex-
pression of miR-106b led to less cell tube formation in
the planar Matrigel assay. In contrast, the reduction
of miR-106b levels by inhibitor transfection caused
increased endothelial tube formation (Fig. 2e-j). Taken
together, these findings reveal that miRNA-106b has
anti-angiogenic properties in endothelial cells while no
obvious effect on apoptosis.
Screening the targets of miR-106b
Knowing that miR-106b regulates angiogenesis in endo-
thelial cells, we got down to finding out the potential
target genes of miR-106b which could be the most key
processes involved in the observed effects we mentioned
above. A combination of bioinformatic algorithms (Tar-
getscan, MiRanda and PicTar) were used to predict can-
didate target genes related to angiogenesis, as a result,
VEGFA, JAK1, STAT3, MAPK14, IL-8(Interleukin-8),
PDGFRA(Platelet-Derived Growth Factor Receptor A)
were selected.
Through reviewing articles, we summarized several
target genes of miR-106b ~ 25 cluster which were vali-
dated by other researches (Table 1).
In order to find out how those target genes take part
in the angiogenesis processes, we acquired several key
signaling pathways involving the candidate target genes
by searching currently known signaling pathways related
to angiogenesis through Kyoto Encyclopedia of Genes
and Genomes (KEGG), the result showed VEGFA, JAK1,
STAT3 and MAPK14 all have irreplaceable roles in
angiogenesis (Fig. 3a).
At last, we displayed all the predicted target genes and
explored the intersections among them. Then we even-
tually focused on VEGFA, JAK1, STAT3 and MAPK14
(Fig. 3b).
MiR-106b reduces STAT3 expression in endothelial cells
Given that miRNAs function mainly by mRNA repres-
sion, we were particularly interested in down-regulated
mRNAs because they may be direct miRNA targets.
Analysis performed by qRT-PCR revealed that VEGFA,
JAK1 and MAPK14 expression was unaffected by miR-
106b up or down regulation in HUVECs while STAT3
was regulated by miR-106b as revealed by qRT-PCR and
also by Western blot. Our study manifested that overex-
pressed miR-106b represses STAT3 expression not only
on mRNA but also on protein levels in endothelial cells,
while miR-106b inhibition give rise to STAT3 up-
regulation (Fig. 4).
(See figure on previous page.)
Fig. 2 a-l Flow cytometry analysis and tube formation assay of HUVECs after transfection. a-d X axis represents fluorescence intensity, while Y axis
represents counts of HUVECs. M1 labeled interval stands for the FITC fluorescence intensity range identified by flow cytometry. No matter transfected with
miR-106b mimic or miR-106b inhibitor, most of the HUVECs were on the left side of M1 interval, meaning that most of the cells were not apoptotic so they
can’t be labeled by fluorescence. e-g Less tubes were formed in the miR-106b mimic transfection group than the other two groups, furthermore, the
discontinuity of tube wall was more significant than the other two groups as well (of 10× magnification). h-j On the contrary, HUVECs of miR-106b inhibitor
transfection group formed more tubes with more intactness than the other two groups (of 25× magnification). k, l Differences between different treatment
groups are significant, data are presented as means ± SEM. **P<0.05, n= 4
Table 1 Currently-known biological functions of miR-106b ~ 25 cluster
microRNAs Biological function Target genes References
miR-93 Preventing the progression of diabetic nephropathy VEGF [22]
miR-106b ~ 25 Inhibiting cell-cycle arrest and apoptosis p21,Bim [15, 23]
miR-106b Impairing cellular cholesterol efflux and increasing the levels of secreted amyloid β ABCA1 [24]
miR-106b,93 Inhibiting brown adipocyte differentiation [25]
miR-106b ~ 25 Inhibiting apoptosis and promoting tube formation PTEN [16]
miR-25 Suppressing Cdk inhibitors and promoting cell proliferation p57Kip2 [23]
miR-106b Inhibiting cell cycle arrest and promoting cell proliferation E2F1,E2F3 [26]
miR-106b Activating p73 apoptotic signaling in Chronic Lymphocytic Leukemia cells ITCH [27]
miR-106b Maintaining the structural homeostasis of developing lung epithelium MAPK14,STAT3 [17]
miR-93 Inducing embryonic stem cell differentiation STAT3 [28]
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MiR-106b interfere STAT3′s expression by direct target
impact in endothelial cells
To identify whether STAT3 is a direct target of miR-
106b, we constructed a luciferase reporter vector encod-
ing the complete 3′UTR of STAT3 [WT (Wildtype)
STAT3 3′UTR] as well as a control vector containing
mismatches in predicted miR-106b binding site [Mut
(Mutant) STAT3 3′UTR] (Fig. 5a). Co-transfection of the
WT STAT3 3′UTR plasmid and miR-106b mimic in
293 T cells showed obvious decrease in fluorescence in-
tensity whereas Mut STAT3 3′UTR didn’t change lucif-
erase gene expression, which validated that STAT3
mRNA is a direct target of miR-106b (Fig. 5b).
Discussion
Notably, miR-106b ~ 25 cluster, miR-17 ~ 92 cluster and
miR-106a ~ 363 cluster are paralogs [9],which are
located on different chromosomes, derived from a
unique gene that underwent a series of duplications,
mutations, and loss of individual miRNAs during the
early evolution of vertebrates, resulting in the selection
of similar but not identical clusters. Based on their seed
sequences which are the regions considered most im-
portant for target selection (nucleotides 2–7), the miR-
NAs of these clusters can be grouped into four families:
the miR-17 family (miR-17, miR-20a/b, miR-106a/b, and
miR-93); the miR-18 family (miR-18a/b); the miR-19
family (miR-19a/b); and the miR-25 family (miR-25,
miR-92a, and miR-363). Up till now, plenty of researches
have revealed us a profile of up-regulated miR-17 ~ 92
cluster in tumors [10–12], which could promote angio-
genesis [13]. Exceptionally, miR-92a has been proven to
inhibit angiogenesis in vitro and in vivo [14]. Petrocca et al.
[15] discovered that the miR-106b ~ 25 cluster could be
A
B
Fig. 3 a, b Signaling pathway obtained from KEGG database and schematic diagram of searching candidate target genes. a Among all the pathway, we
could easily find the genes associated with angiogenesis, which are, respectively, MAPK14, JAK1, STAT1, STAT3, and VEGF. b We merged genes derived
from bioinformatics algorithms, genes proven by literatures and famous angiogenesis-related genes to confirm the final candidate target genes, which
are VEGFA, JAK1, STAT3 and MAPK14
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activated by E2F1 in a subset of human gastric tumors. In
turn, miR-106b and miR-93 regulated E2F1 expression.
Eventually, up-regulation of these miRNAs impaired the
TGFβ tumor suppressor pathway through interfering with
the expression of CDKN1A (p21Waf1/Cip1) and BCL2L11
(Bim). Interestingly, miR-17 ~ 92 cluster synergistically
participates in this process. As we previously stated, miR-
17 ~ 92 cluster has been proven pivotal in angiogenesis,
given the similar biological functions of these two clusters,
miR-106b ~ 25 cluster could probably be involved in
angiogenesis as well. This idea was recently confirmed by
Semo et al [16], who discovered that post-ischemic
vascularization in miR-106b ~ 25 knockout mice models
of hindlimb ischemia is impaired and subsequent re-
expression of miR-106b ~ 25 via local injection of plas-
mids encoding this cluster can partially reverse the blood
supplies. Meanwhile miR-106b ~ 25 knockout bone mar-
row stromal cells(BMSCs) shows the susceptibilities to
apoptosis and decreasing abilities of paracrine and tube
formation. All these suggest a pro-angiogenic effect of
miR-106b ~ 25 cluster in BMSCs, but the conclusions
about miR-106b ~ 25’s pro-angiogenic role in endothelial
cells seems not that persuasive, since over-expression of
miR-106b ~ 25 in H5V cells has no effect on the tube for-
mation in vitro Matrigel assay. Therefore, to date, the spe-
cific role of miR-106b ~ 25 related to angiogenesis in
endothelial cells is still obscure. In this study we investi-
gated miR-106b’s role in angiogenesis through observing
changes in general functions of endothelial cells after up
and down regulating miR-106b’s expression, which dem-
onstrates that miR-106b over-expression in endothelial
cells inhibits tube formation while the reduction of miR-
106b’s level shows the opposite. No significant difference
in TUNEL assay suggests that miR-106b’s expression has
no obvious effect on apoptosis in endothelial cells.
Knowing that miR-106b modulates angiogenesis in
endothelial cells, we wondered how these processes
could be achieved. Since miRNAs function through inhi-
biting expression of their target genes, seeking out the
potential target genes of miR-106b would explain the
pivotal mechanisms giving rise to the observed effects.
Fig. 4 a-l QRT-PCR results of different candidate genes and western-
blot results of STAT3 protein expression among groups under
different treatments. a-h VEGFA, JAK1 and MAPK14 expression levels
are not significantly affected by miR-106b up or down regulation in
HUVECs (P >0.05, n = 6). Meanwhile, over-expressed miR-106b represses
STAT3 mRNA expression in HUVECs, while miR-106b inhibition lead to
an increase in STAT3 expression. Results are shown as mean ± SEM
representative of at least three independent experiments. **P <0.05,
n = 6. i-l Identical to the outcome obtained from qRT-PCR, miR-106b
mimic transfection inhibits STAT3 expression while miR-106b inhibitor
transfection enhances STAT3 expression. Data are shown as mean ±
SEM representative of at least three independent experiments.
**P <0.05, n = 6
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Angiogenesis-related target genes were screened out via
a combination of bioinformatic algorithms (Targetscan,
MiRanda and PicTar), consequently, VEGFA, JAK1,
STAT3, MAPK14, IL-8, PDGFRA were selected to be the
candidate genes. With the purpose of choosing the most
likely genes, we consulted a certain amount of literatures
to search currently known target genes associated with
miR-106b ~ 25 cluster. As a member of miR-17 family,
A
B
Fig. 5 a, b Luciferase assays of miR-106b binding sites on human STAT3 3′UTR. a Schematic representation of the 3′ untranslated region (3′UTR) of
STAT3 mRNA with the predicted target sites for miR-106b. The seed sequences of miR-106b are in green letters, the target sites of STAT3 mRNA
are in red letters, and the mutated miR-106b-binding sites are in gray boxes. b HUVECs were transfected with either wild-type 3′UTR STAT3 or
mutant 3′UTR STAT3, along with the miR-106b mimic. hRluc (renilla luciferace gene) was reporter gene, while hluc (firefly luciferace gene) was
reference gene as internal control. Results are shown as mean ± SEM representative of three independent experiments, there are significant differences
in fluorescence intensity between STAT3-WT +NC transfection group and STAT3-WT +miR-106b mimic transfection group and also between STAT3-WT +
miR-106b mimic transfection group and STAT3-MUT +miR-106b mimic transfection group.** P< 0.05, n= 3
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miR-106b shares an identical seed region with other
family members. Therefore, it can be inferred that they
may share a number of target genes. Studies showed
miR-17 family contributes to maintain the structure sta-
bility of alveolar epithelial cells in growth and develop-
ment process by targeting MAPK14 and STAT3 [17],
meanwhile other evidence demonstrated that miR-17
family function as direct endogenous repressors of the
VEGFA in nasopharyngeal carcinoma cells [18].
Researches of endothelial cells manifested that miR-17
has an anti-angiogenic function by inhibiting the expres-
sion of target gene JAK1 and subsequent repression of
JAK/STAT signaling in endothelial cells [19]. Kyoto
Encyclopedia of Genes and Genomes (KEGG) provided
us with several angiogenesis-associated signaling path-
ways involving VEGFA, JAK1, STAT1, STAT3 and
MAPK14, which are turn out to be crucial in angiogen-
esis processes.
Taken together, we speculate that MAPK14, STAT3,
VEGFA and JAK1 could be the potential target genes
of miR-106b. Based on this speculation, our study fo-
cused on how miR-106b act on its target in endothe-
lial cell-related angiogenesis. Data gathered from the
qRT-PCR and Western blot demonstrated that up or
down regulation of miR-106b in HUVECs has no in-
fluence on expression of VEGFA, JAK1 and MAPK14,
while expression of STAT3 would be repressed by
miR-106b. Therefore, there is every reason to suspect
that miR-106b inhibits STAT3 expression via directly
binding to it. Consistent with Carraro G et al [17],
luciferase reporter assay showed obvious decrease in
fluorescence intensity when WT STAT3 3′UTR plas-
mid and miR-106b mimic co-transfected together
whereas Mut STAT3 3′UTR didn’t change luciferase
gene expression, which verified that miR-106b inhibits
STAT3 expression by a direct target effect. Thus, our
research explicitly revealed miR-106b suppresses
STAT3 expression, which due to a direct effect medi-
ated by miR-106b, that is to say, miR-106b exhibits
an anti-angiogenic function by inhibiting STAT3 ex-
pression in endothelial cells.
In this research, we have confirmed miR-106b directly
inhibited STAT3 expression with no obvious effect on
MAPK14,VEGFA and JAK1, which was partially consist-
ent with Carraro’s [17] discovery that miR-17 family
downregulate STAT3 and MAPK14 expression in lung
epithelial cells. As is known to all, STAT3 pathway was
identified as key components linking cytokine signals to
transcriptional events in cells, meanwhile STAT proteins
can regulate many pathways including cell-cycle progres-
sion, apoptosis, tumor angiogenesis, tumor-cell invasion
and metastasis, and tumor-cell evasion of the immune
system [20]. Niu et al [21] demonstrated that VEGF ex-
pression correlated with STAT3 activity in various
human cancer cell lines. An activated STAT3 mutant
upregulated VEGF expression and promoted tumor
angiogenesis. Moreover, interrupting STAT3 signaling in
tumor cells downregulated VEGF expression and inhib-
ited angiogenesis. Apparently, STAT3 pathway promote
angiogenesis primarily through upregulating VEGFA ex-
pression, however, our results showed that VEGFA level
was not affected. We considered STAT3 may regulate
other angiogenic factors, such as HIF-1α and FGF2, to
promote angiogenesis process. Originally, our research
was designed to find out miR-106b’s function in endo-
thelial cells based on the predicted target genes of miR-
106b through TargetScan/MiRanda/PicTar algorithms,
according to which, HIF-1α and FGF2 are not predicted
target genes of miR-106b. Therefore, detecting those fac-
tors does not conform to our original research intention.
Nevertheless, in our subsequent research plan, we are
focusing on this issue to ensure its completion.
Conclusions
Our research found that miR-106b restrains angiogenesis
processes in endothelial cells, meanwhile expression of
STAT3 is significantly repressed, which was subsequently
proven to be a direct effect between miR-106b and STAT3.
Given the importance of STAT3 in angiogenesis, we con-
clude that miR-106b exhibits an anti-angiogenic effect in
endothelial cells through directly binding to STAT3.
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